Literature DB >> 25178969

The protein DIIIC-2, aggregated with a specific oligodeoxynucleotide and adjuvanted in alum, protects mice and monkeys against DENV-2.

Lázaro Gil1, Ernesto Marcos1, Alienys Izquierdo2, Laura Lazo1, Iris Valdés1, Peris Ambala3, Lucy Ochola3, Rikoi Hitler3, Edith Suzarte1, Mayling Álvarez2, Prisilla Kimiti3, James Ndung'u3, Thomas Kariuki3, María Guadalupe Guzmán2, Gerardo Guillén1, Lisset Hermida1.   

Abstract

Previously, we reported the ability of the chimeric protein DIIIC-2 (domain III of the dengue envelope protein fused to the capsid protein of dengue-2 virus), to induce immunity and protection in mice, when it is highly aggregated with a non-defined oligodeoxynucleotide (ODN) and adjuvanted in alum. In this work, three different defined ODNs were studied as aggregating agents. Our results suggest that the nature of the ODN influences the capacity of protein DIIIC-2 to activate cell-mediated immunity in mice. Consequently, the ODN 39M was selected to perform further experiments in mice and nonhuman primates. Mice receiving the preparation 39M-DIIIC-2 were solidly protected against dengue virus (DENV) challenge. Moreover, monkeys immunized with the same preparation developed neutralizing antibodies, as measured by four different neutralization tests varying the virus strains and the cell lines used. Two of the immunized monkeys were completely protected against challenge, whereas the third animal had a single day of low-titer viremia. This is the first work describing the induction of short-term protection in monkeys by a formulation that is suitable for human use combining a recombinant protein from DENV with alum.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25178969     DOI: 10.1038/icb.2014.63

Source DB:  PubMed          Journal:  Immunol Cell Biol        ISSN: 0818-9641            Impact factor:   5.126


  43 in total

1.  Antibodies targeting dengue virus envelope domain III are not required for serotype-specific protection or prevention of enhancement in vivo.

Authors:  Katherine L Williams; Wahala M P B Wahala; Susana Orozco; Aravinda M de Silva; Eva Harris
Journal:  Virology       Date:  2012-04-25       Impact factor: 3.616

2.  CpG oligodeoxynucleotides as DNA adjuvants in vertebrates and their applications in immunotherapy.

Authors:  Hso-Chi Chaung
Journal:  Int Immunopharmacol       Date:  2006-06-28       Impact factor: 4.932

3.  A recombinant fusion protein containing the domain III of the dengue-2 envelope protein is immunogenic and protective in nonhuman primates.

Authors:  Lisset Hermida; Lídice Bernardo; Jorge Martín; Mayling Alvarez; Irina Prado; Carlos López; Beatriz de la C Sierra; Rafael Martínez; Rosmary Rodríguez; Aída Zulueta; Ana B Pérez; Laura Lazo; Delfina Rosario; Gerardo Guillén; María G Guzmán
Journal:  Vaccine       Date:  2006-02-03       Impact factor: 3.641

4.  An alphavirus vector-based tetravalent dengue vaccine induces a rapid and protective immune response in macaques that differs qualitatively from immunity induced by live virus infection.

Authors:  Laura J White; Carlos A Sariol; Melissa D Mattocks; Wahala Wahala M P B; Vorraphun Yingsiwaphat; Martha L Collier; Jill Whitley; Rochelle Mikkelsen; Idia V Rodriguez; Melween I Martinez; Aravinda de Silva; Robert E Johnston
Journal:  J Virol       Date:  2013-01-09       Impact factor: 5.103

5.  Human peripheral blood cells differentially recognize and respond to two distinct CPG motifs.

Authors:  D Verthelyi; K J Ishii; M Gursel; F Takeshita; D M Klinman
Journal:  J Immunol       Date:  2001-02-15       Impact factor: 5.422

6.  Simplified plaque reduction neutralization assay for dengue viruses by semimicro methods in BHK-21 cells: comparison of the BHK suspension test with standard plaque reduction neutralization.

Authors:  D M Morens; S B Halstead; P M Repik; R Putvatana; N Raybourne
Journal:  J Clin Microbiol       Date:  1985-08       Impact factor: 5.948

7.  Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial.

Authors:  Arunee Sabchareon; Derek Wallace; Chukiat Sirivichayakul; Kriengsak Limkittikul; Pornthep Chanthavanich; Saravudh Suvannadabba; Vithaya Jiwariyavej; Wut Dulyachai; Krisana Pengsaa; T Anh Wartel; Annick Moureau; Melanie Saville; Alain Bouckenooghe; Simonetta Viviani; Nadia G Tornieporth; Jean Lang
Journal:  Lancet       Date:  2012-09-11       Impact factor: 79.321

8.  An in-depth analysis of original antigenic sin in dengue virus infection.

Authors:  Claire M Midgley; Martha Bajwa-Joseph; Sirijitt Vasanawathana; Wannee Limpitikul; Bridget Wills; Aleksandra Flanagan; Emily Waiyaiya; Hai Bac Tran; Alison E Cowper; Pojchong Chotiyarnwong; Pojchong Chotiyarnwon; Jonathan M Grimes; Sutee Yoksan; Prida Malasit; Cameron P Simmons; Juthathip Mongkolsapaya; Gavin R Screaton
Journal:  J Virol       Date:  2010-10-27       Impact factor: 5.103

9.  Partial nucleotide and amino acid sequences of the envelope and the envelope/nonstructural protein-1 gene junction of four dengue-2 virus strains isolated during the 1981 Cuban epidemic.

Authors:  M G Guzman; V Deubel; J L Pelegrino; D Rosario; M Marrero; C Sariol; G Kouri
Journal:  Am J Trop Med Hyg       Date:  1995-03       Impact factor: 2.345

10.  Primary and secondary infections of Macaca fascicularis monkeys with Asian and American genotypes of dengue virus 2.

Authors:  Lidice Bernardo; Alienys Izquierdo; Irina Prado; Delfina Rosario; Mayling Alvarez; Emidalys Santana; Jorge Castro; Rafael Martínez; Rosmari Rodríguez; Luis Morier; Gerardo Guillén; María G Guzmán
Journal:  Clin Vaccine Immunol       Date:  2007-12-19
View more
  7 in total

1.  Protective cellular immune response against hepatitis C virus elicited by chimeric protein formulations in BALB/c mice.

Authors:  Santa Olivera; Angel Perez; Viviana Falcon; Dioslaida Urquiza; Dagmara Pichardo; Gillian Martinez-Donato
Journal:  Arch Virol       Date:  2020-02-03       Impact factor: 2.574

2.  Evaluation of protection induced by a dengue virus serotype 2 envelope domain III protein scaffold/DNA vaccine in non-human primates.

Authors:  Sean P McBurney; Justine E Sunshine; Sarah Gabriel; Jeremy P Huynh; William F Sutton; Deborah H Fuller; Nancy L Haigwood; William B Messer
Journal:  Vaccine       Date:  2016-04-13       Impact factor: 3.641

3.  The tetravalent formulation of domain III-capsid proteins recalls memory B- and T-cell responses induced in monkeys by an experimental dengue virus infection.

Authors:  Lázaro Gil; Laura Lazo; Iris Valdés; Edith Suzarte; Phuong Yen; Rosa Ramírez; Mayling Álvarez; Le T Dung; Karem Cobas; Ernesto Marcos; Yusleidi Pérez; María G Guzmán; Ngyen D Hien; Gerardo Guillén; Lisset Hermida
Journal:  Clin Transl Immunology       Date:  2017-06-23

4.  Comparative proteomic analysis of growth hormone secretagogue A233 treatment of murine macrophage cells J774A.2 indicates it has a role in antiviral innate response.

Authors:  Rebeca Martínez; Teresa Núñez de Villavicencio-Díaz; Aniel Sánchez; Yassel Ramos; Jesús Noda Ferro; Lázaro Gil González; Milagros Méndez; Elsa Rodríguez; Ernesto Marcos; Belinda Sánchez; Yordanka Masforrol; Hilda Garay; Fernando Albericio; Lisset Hermida; Luis Javier González; Eva Vonasek; Mario P Estrada; Vladimir Besada
Journal:  Biochem Biophys Rep       Date:  2016-01-14

Review 5.  Recent Developments in Recombinant Protein-Based Dengue Vaccines.

Authors:  Nagesh K Tripathi; Ambuj Shrivastava
Journal:  Front Immunol       Date:  2018-08-23       Impact factor: 7.561

Review 6.  Structure and function of capsid protein in flavivirus infection and its applications in the development of vaccines and therapeutics.

Authors:  Xingcui Zhang; Yanting Zhang; Renyong Jia; Mingshu Wang; Zhongqiong Yin; Anchun Cheng
Journal:  Vet Res       Date:  2021-06-30       Impact factor: 3.683

7.  Screening for immune response against Dengue virus in Vietnamese non-human primates: implications for vaccine developers.

Authors:  Laura Lazo Vázquez; Edith Suzarte Portal; Jorge Castro Velazco; Phuong Yen; Le Trung Dung; Lázaro Gil González; Iris Valdés Prado; Ernesto Marcos López; Karem Cobas Acosta; Nguyen Dang Hien; Gerardo Guillén Nieto; Lisset Hermida Cruz
Journal:  Clin Transl Immunology       Date:  2017-03-24
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.